Rob Volansky

WASHINGTON — Lorecivivint is superior to placebo for improving pain, function and structure at 12 months and beyond in patients with knee osteoarthritis, according to data presented at ACR Convergence 2024.

WASHINGTON — Practices that join the American College of Rheumatology's RISE registry report “doubled to tripled” rates of improvement in rheumatoid arthritis function and disease activity assessment, according to data.

WASHINGTON — Patients with polymyalgia rheumatica were more likely to discontinue steroids after treatment with sarilumab than methotrexate, according to data presented at ACR Convergence 2024.

WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or spondyloarthritis does not significantly

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs.

WASHINGTON — A focus on patient follow-up, standardized medication adherence and barriers assessments can reduce racial and ethnic disparities in juvenile idiopathic arthritis, according to a speaker at ACR Convergence 2024.

WASHINGTON — Addressing economic insecurities through a social worker “could improve” physical function and other patient reported outcomes in systemic lupus erythematosus, according to a speaker at ACR Convergence 2024.

WASHINGTON — Children with lupus from areas of lower socioeconomic opportunity experience more severe disease complications and poorer outcomes than

WASHINGTON — Increased reimbursement and expanded educational opportunities are two key solutions to the workforce shortage in adult and pediatric rheumatology, according to two speakers at ACR Convergence 2024.

WASHINGTON — Addressing burnout in rheumatology will require attention to personal exhaustion and depersonalization, as well as systemic business-of-medicine issues, according to a speaker at ACR Convergence 2024.